Lingzhi Zhang

Dr. Lingzhi Zhang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2018 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
SPShunshun Pan
Shunshun Pan
XDXuming Deng
Xuming Deng
SSShili Sun
Shili Sun
XLXingfei Lai
Xingfei Lai
LSLingli Sun
Lingli Sun
YHYahui Huang
Yahui Huang

17 June 2024 in Foods
Verified
Journal Article
Open access
PDF file
ZZZhenbiao Zhang
Zhenbiao Zhang
XDXuming Deng
Xuming Deng
RCRuohong Chen
Ruohong Chen
QLQiuhua Li
Qiuhua Li
LSLingli Sun
Lingli Sun
LZLingzhi Zhang
Lingzhi Zhang
The bioactivity of tea polysaccharides (TPs) has been widely reported, but studies to date have focused on green tea. Some human health investigations have implied that black tea may possess potential antidiabetic effects, but less is known about their potential role and related antidiabetic mechanism. The present study was, therefore, conducted to investigate the chemical properties and antidiabetic activity of TPs from black tea. Monosaccharide composition revealed that Alduronic acid (77.8 mol%) considerably predominated in the fraction. TP conformation analysis indicated that three components in TPs were all typical of high-branching structures. Oral administration of TPs could effectively alleviate fasting blood glucose in type 2 diabetes mellitus (T2D) mice, with the values 23.6 ± 1.42, 19.6 ± 2.25, and 16.4 ± 2.07 mmol/L in the 200, 400, and 800 mg/kg·BW groups, respectively. Among these TPs groups, the 800 mg/kg·BW groups significantly decreased by 37.88% when compared with the T2D+water group (p < 0.05). Further studies demonstrated that TP treatment upregulated the expression of p-Akt/p-PI3K (p < 0.001). Additionally, TP treatment significantly promoted glucose transporter protein 2 (GLUT2) translocation in the liver (p < 0.001). These findings suggest that TPs from black tea protect against T2D by activating PI3K/Akt/GLUT2 signaling and might serve as a novel therapeutic candidate for T2D.